Salim Yusuf Selected Research

Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)

10/2022	Pharmacogenomic study of heart failure and candesartan response from the CHARM programme.
1/2020	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study.
1/2019	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
12/2017	Secondary CV Prevention in South America in a Community Setting: The PURE Study.
1/2016	Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
10/2015	Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study.
4/2015	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus.
3/2014	Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
4/2013	Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.
2/2013	Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Salim Yusuf Research Topics

Disease

179	Stroke (Strokes) 12/2022 - 01/2002
123	Heart Failure 10/2022 - 01/2002
113	Myocardial Infarction 12/2022 - 01/2002
113	Hemorrhage 11/2022 - 02/2003
112	Cardiovascular Diseases (Cardiovascular Disease) 11/2022 - 01/2002
99	Atrial Fibrillation 01/2022 - 07/2002
46	Hypertension (High Blood Pressure) 07/2022 - 01/2002
39	Acute Coronary Syndrome 11/2019 - 09/2002
34	Vascular Diseases (Vascular Disease) 10/2022 - 03/2002
32	Embolism (Embolus) 04/2021 - 09/2009
29	Coronary Artery Disease (Coronary Atherosclerosis) 12/2022 - 01/2002
27	Ischemic Stroke 05/2022 - 09/2008
24	Peripheral Arterial Disease 12/2022 - 07/2007
21	Thrombosis (Thrombus) 06/2022 - 02/2003
21	Diabetes Mellitus 01/2020 - 03/2002
21	Unstable Angina 01/2018 - 09/2002
19	Atherosclerosis 01/2022 - 01/2002
19	ST Elevation Myocardial Infarction 01/2018 - 01/2005
16	Type 2 Diabetes Mellitus (MODY) 01/2020 - 11/2003
16	Left Ventricular Dysfunction 03/2014 - 01/2002
14	Hypotension (Low Blood Pressure) 10/2022 - 09/2003
14	Ischemia 12/2020 - 12/2004
13	Abdominal Obesity 01/2022 - 01/2003
12	Neoplasms (Cancer) 01/2022 - 10/2004
11	Coronary Disease (Coronary Heart Disease) 12/2017 - 09/2003
11	Albuminuria 07/2016 - 03/2003
11	Glucose Intolerance 07/2014 - 02/2003
10	Cognitive Dysfunction 06/2022 - 10/2008
10	Obesity 01/2022 - 04/2007
9	Chronic Renal Insufficiency 12/2021 - 04/2007
9	Hyperkalemia 12/2014 - 01/2002
8	Heart Arrest (Cardiac Arrest) 01/2021 - 09/2004
8	Insulin Resistance 01/2018 - 01/2002
7	Infections 02/2022 - 05/2014
7	Renal Insufficiency (Renal Failure) 01/2020 - 01/2002
6	Infarction (Infarctions) 10/2020 - 11/2005
6	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2018 - 09/2008
5	Hemorrhagic Stroke 01/2022 - 09/2009

Drug/Important Bio-Agent (IBA)

89	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2022 - 04/2002
63	candesartanIBA 10/2022 - 09/2003
56	Ramipril (Altace)FDA LinkGeneric 01/2021 - 01/2002
52	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2022 - 01/2002
45	Telmisartan (Micardis)FDA Link 01/2021 - 01/2002
44	Warfarin (Coumadin)FDA LinkGeneric 01/2020 - 09/2009
42	Dabigatran FDA Link 01/2020 - 09/2009
36	Clopidogrel (Plavix)FDA Link 11/2021 - 09/2002
33	RivaroxabanIBA 12/2022 - 01/2017
33	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 02/2003
30	AnticoagulantsIBA 11/2021 - 02/2003
29	CreatinineIBA 01/2022 - 01/2002
29	Angiotensin Receptor AntagonistsIBA 12/2017 - 10/2004
27	LipidsIBA 10/2022 - 09/2004
25	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2005
23	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2019 - 01/2002
21	Vitamin K FDA Link 04/2021 - 05/2009
20	Pharmaceutical PreparationsIBA 10/2022 - 01/2002
19	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 12/2009
18	SodiumIBA 09/2021 - 11/2011
17	Fondaparinux (Arixtra)FDA Link 05/2014 - 03/2005
16	apixabanIBA 04/2021 - 03/2010
16	Insulin (Novolin)FDA Link 01/2019 - 12/2004
14	CholesterolIBA 11/2022 - 07/2007
13	ApolipoproteinsIBA 05/2022 - 09/2004
12	Irbesartan FDA LinkGeneric 01/2020 - 11/2007
11	omega-Chloroacetophenone (Mace)IBA 10/2022 - 05/2014
11	PotassiumIBA 01/2021 - 12/2004
11	Insulin Glargine (Lantus)FDA Link 01/2019 - 01/2008
11	Heparin (Liquaemin)FDA LinkGeneric 05/2014 - 02/2003
10	Rosuvastatin Calcium (Crestor)FDA Link 01/2022 - 01/2015
9	Apolipoproteins B (ApoB)IBA 05/2022 - 09/2004
9	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 09/2011
9	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 09/2005
9	Enalapril FDA LinkGeneric 03/2014 - 12/2002
8	Lipoproteins (Lipoprotein)IBA 05/2022 - 07/2008
8	Troponin T (Troponin T1)IBA 01/2022 - 01/2011
8	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 07/2006
8	HDL CholesterolIBA 01/2022 - 07/2003
8	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2021 - 05/2016
8	Enoxaparin (Lovenox)FDA LinkGeneric 05/2011 - 12/2005
7	Proteins (Proteins, Gene)FDA Link 11/2021 - 05/2005
6	AlbuminsIBA 01/2021 - 12/2006
6	LDL CholesterolIBA 01/2020 - 05/2016
6	Factor Xa InhibitorsIBA 01/2018 - 03/2005
6	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 04/2016 - 12/2002
6	HomocysteineIBA 02/2012 - 01/2002
5	C-Reactive ProteinIBA 01/2022 - 07/2006
5	Triglycerides (Triacylglycerol)IBA 01/2021 - 07/2003
5	ORALIT (ORS)IBA 10/2019 - 11/2005
5	Digoxin (Digitek)FDA LinkGeneric 10/2019 - 12/2002

Therapy/Procedure

136	Therapeutics 10/2022 - 01/2002
28	Percutaneous Coronary Intervention 01/2020 - 02/2003
20	Secondary Prevention 11/2020 - 03/2002
12	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 06/2022 - 11/2003
8	Surgical Amputation (Amputations) 01/2022 - 11/2013
7	Long-Term Care 10/2019 - 04/2012
7	Stents 01/2018 - 09/2010
6	Length of Stay 01/2020 - 07/2002
6	Thrombectomy 01/2018 - 03/2014
6	Drug Therapy (Chemotherapy) 01/2018 - 02/2010
5	Cardiopulmonary Bypass (Heart-Lung Bypass) 01/2020 - 03/2013